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AbstrAct
Introduction Hyperglucagonemia is a key 
pathophysiological driver of type 2 diabetes. Although 
Roux- en- Y gastric bypass (RYGB) is a highly effective 
treatment for diabetes, it is presently unclear how surgery 
alters glucagon physiology. The aim of this study was 
to characterize the behavior of proglucagon- derived 
peptide (glucagon, glucagon- like peptide-1 (GLP-1), 
oxyntomodulin, glicentin) secretion after RYGB surgery.
Research design and methods Prospective study of 19 
patients with obesity and pre- diabetes/diabetes undergoing 
RYGB. We assessed the glucose, insulin, GLP-1, glucose- 
dependent insulinotropic peptide (GIP), oxyntomodulin, 
glicentin and glucagon responses to a mixed- meal test 
(MMT) before and 1, 3 and 12 months after surgery. 
Glucagon was measured using a Mercodia glucagon ELISA 
using the ‘Alternative’ improved specificity protocol, which 
was validated against a reference liquid chromatography 
combined with mass spectrometry method.
Results After RYGB, there were early improvements in 
fasting glucose and glucose tolerance and the insulin 
response to MMT was accelerated and amplified, in 
parallel to significant increases in postprandial GLP-1, 
oxyntomodulin and glicentin secretion. There was a 
significant decrease in fasting glucagon levels at the later 
time points of 3 and 12 months after surgery. Glucagon 
was secreted in response to the MMT preoperatively and 
postoperatively in all patients and there was no significant 
change in this postprandial secretion. There was no 
significant change in GIP secretion.
Conclusions There is a clear difference in the dynamics of 
secretion of proglucagon peptides after RYGB. The reduction 
in fasting glucagon secretion may be one of the mechanisms 
driving later improvements in glycemia after RYGB.
Trial registration number NCT01945840.
InTRoduCTIon 
Bariatric surgery is currently considered to 
be the most effective treatment for obesity 
and type 2 diabetes.1 The beneficial effects 
of weight loss as well as the improvement in 
other metabolic parameters are at least partly 
mediated through postoperative changes of 
gut hormone secretion.2–4 Roux- en- Y gastric 
bypass (RYGB) is characterized by enhanced 
postprandial glucagon- like peptide-1 (GLP-
1), oxyntomodulin and peptide YY (PYY) 
secretion, leading to enhanced insulin 
significance of this study
What is already known about this subject?
 ► Roux- en- Y gastric bypass (RYGB) is a highly effec-
tive treatment for diabetes and obesity.
 ► Diabetes is characterized by hyperglucagonemia 
and hyperglycemia.
 ► The effects of RYGB on glucagon secretion are not 
precisely known with contradictory effects seen in 
previous studies.
 ► The contradictory findings of these previous studies may 
be due to cross- reaction of the employed glucagon im-
munoassays with related proglucagon- derived peptides.
What are the new findings?
 ► We validated a sensitive and specific immunoassay 
for measurement of postprandial glucagon levels in 
patients who have had RYGB, against a reference 
mass- spectrometry assay.
 ► We found that fasting glucagon was reduced at 3 
and 12 months after RYGB surgery.
 ► The postprandial secretion of glucagon in response to 
the mixed- meal stimulus was not significantly altered.
 ► This contrasted with the other proglucagon- derived 
peptides (glucagon- like peptide-1, oxyntomodulin) 
which exhibited no significant change in fasting lev-
els but marked enhancements of postprandial se-
cretion at earlier time points after surgery.
How might these results change the focus of 
research or clinical practice?
 ► The reduction of glucagon secretion (glucagonos-
tasis) appears to be related to the continuing im-
provement in glycemia at later time points after 
RYGB.
 ► The Mercodia immunoassay, using an Alternative 
high- stringency protocol to minimize detection of other 
proglucagon- derived peptides, is suitable for the study 
of glucagon levels in patients who have had RYGB.
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Table 1 Clinical characteristics of the prospectively 
studied RYGB surgery patients (n=19)
Age (years) 49.7 (13.0)
Gender (F:M) 16:3
Preoperative HbA1c (mmol/mol) 56.8 (14.3)
Postoperative HbA1c 12 months (mmol/mol) 37.4 (5.7)
Height (m) 1.64 (0.08)
Preoperative weight (kg) 115.3 (25.3)
Weight 1 month (kg) 105.5 (24.2)
Weight loss 1 month (%) 8.7% (2.6%)
Weight 3 months (kg) 96.7 (21.1)
Weight loss 3 months (%) 17.2% (3.5%)
Weight 12 months (kg) 80.6 (16.3)
Weight loss 12 months (%) 29.5% (7.3%)
Mean (SD) shown.
RYGB, Roux- en- Y gastric bypass.
secretion, early resolution of diabetes, long- term appetite 
suppression, reduced caloric intake and weight loss.5–8 
Although infusion of GLP-1, oxyntomodulin and PYY 
to replicate the levels seen after RYGB reduces weight 
and normalizes blood glucose in subjects with obesity 
and diabetes, this strategy does not fully replicate all the 
effects of surgery.9 Hence, additional mechanisms may 
also act to mediate the metabolic benefits of RYGB. One 
key hormone that is suspected to be affected by RYGB is 
glucagon. Hyperglucagonemia is etiologically linked to 
the hyperglycemia of diabetes.10 11 In contrast to the well- 
characterized changes in GLP-1, oxyntomodulin and PYY 
secretion after RYGB,8 there are conflicting data in the 
literature on the changes in glucagon physiology after 
bariatric surgery, with various reports of decreases in 
fasting glucagon5 12 versus no significant change13–17; and 
increases in the postprandial glucagon response12–15 17 
versus no significant change18 or even a reduction.5 One 
major factor that may be responsible for this inconsis-
tency is differences in the performance of the immuno-
assays used for the measurement of glucagon, especially 
the technical issue of cross- reactivity between proglu-
cagon peptide species.19 20 Glucagon, oxyntomodulin and 
glicentin are derived from post- translational processing 
of the glucagon precursor, proglucagon: glucagon corre-
sponds to residues 33–61 whereas glicentin maps to 
residues 1–69 and oxyntomodulin to 33–69.21 Differen-
tiating these proglucagon peptide species is therefore 
challenging since they share the same antigenic mid- 
region but also circulate in low levels (0–50 pmol/L) 
demanding high analytical sensitivity.21–23 Of the various 
glucagon assays available the Mercodia sandwich ELISA, 
which detects the N- terminus and C- terminus of the 
peptide, has proven to be a specific and highly sensitive 
assay19 but a recent report suggested that other proglu-
cagon peptide species can still interfere with the deter-
mination of levels using the Standard protocol.24 This 
issue is especially challenging in circumstances such as in 
bypass surgeries where early exposure of neuroendocrine 
L- cells to ingested nutrients can trigger the exaggerated 
secretion of other proglucagon- derived peptides such as 
glicentin and oxyntomodulin. Given the aforementioned 
limitations of the immunoassays, new analytical methods 
such as the combination of liquid chromatography 
combined with mass spectrometry (LC/MS- MS) can be 
used as reference assays.25 However, the ELISAs are more 
analytically sensitive and allow for streamlined processing 
of the multiple samples derived from dynamic testing in 
larger cohorts. For the foreseeable future, immunoassays 
will remain the mainstream assay of choice for physiolog-
ical studies of glucagon. We therefore sought to validate 
the performance of the Mercodia ELISA assay against 
our reference LC/MS- MS assay under the circumstance 
of patients undergoing RYGB, to definitively study the 
evolution of the fasting and postprandial response of 
glucagon and other proglucagon peptides to a mixed- 
meal test (MMT) in a prospectively studied cohort of 
patients undergoing RYGB.
MaTeRIals and MeTHods
Participants
The samples for the comparative assay study were derived 
from dynamic testing (with a standardized 75 g oral 
glucose tolerance test (OGTT) or MMT) of patients after 
RYGB surgery (ref 7 and ISRCTN15283219). Patients 
in the prospective study ( ClinicalTrials. gov) carried a 
diagnosis of impaired fasting glucose, impaired glucose 
tolerance or type 2 diabetes according to WHO criteria, 
and a stable HbA1c of <79 mmol/mol. All patients met 
the UK National Institute for Clinical Excellence criteria 
for bariatric surgery. The clinical characteristics of the 
patients in the prospective study are shown in table 1.
The study took place at the Imperial National Insti-
tute for Health Research Clinical Research Facility at 
Hammersmith Hospital. RYGB surgery was performed 
laparoscopically in a single center (Imperial Weight 
Centre) according to a standardized technique (division 
of the small bowel 50 cm from the ligament of Treitz 
to construct the biliopancreatic limb, construction of 
a 100 cm alimentary limb with a side- to- side entero- 
enterostomy to the biliopancreatic limb, construction of 
a 30–40 mL isolated proximal gastric pouch, endostapler 
anastomosis of the gastric pouch to the alimentary limb) 
by designated surgeons (ARA and SP).
The participants in the prospective study were assessed 
with MMTs before the RYGB surgery and at 1, 3 and 
12 months postoperatively. At each visit, the volunteers 
attended at 08:00 after an overnight fast of at least 
10 hours, without having taken any antidiabetic medi-
cation (if using). The participants were given Ensure 
Compact (14 g protein, 12.9 g of fat, 39.6 g of carbohy-
drates, 330 kcal, 137.5 mL; Abbott) and were directed 
to drink this over 10 min. Blood samples were collected 
via an indwelling cannula placed in the antecubital 
fossa for glucose, insulin, GLP-1, glucose- dependent 
insulinotropic peptide (GIP), oxyntomodulin, glicentin 
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and glucagon levels at baseline and 15, 30, 60, 120 and 
180 min after ingestion.
assays
Plasma samples for glucose were collected in sodium fluo-
ride tubes and serum samples for insulin were collected 
in clot activator tubes (Becton- Dickinson). These were 
analyzed by NW London Pathology using an Abbott 
Architect platform analyzer (Maidenhead, UK; coeffi-
cient of variation (CV) <5% and <10%, respectively). 
Blood samples for gut hormone analysis were collected 
in lithium heparin collection tubes containing 0.1 mL 
of aprotinin (1000 KIU/4 mL of blood; Nordic Pharma 
UK) and a dipeptidyl peptidase 4 inhibitor Diprotin A 
(20 µg/mL blood; Enzo Life Sciences, UK) and chilled 
on ice immediately after collection. After centrifuga-
tion at 4°C, plasma was separated and stored at −80°C 
until analysis. For the comparative assay study, plasma 
glucagon was measured using the Mercodia ELISA, using 
both the Standard manufacturer’s protocol, and the 
Alternative protocol (which includes an additional incu-
bation and wash step) as described in Roberts et al.24 This 
latter protocol was optimized to reduce cross- reactivity 
with other glucagon- related molecules. The lowest level 
of quantification (LLOQ) was 1.5 pmol/L and with 
intra- assay and interassay CV of <10%. Glucagon was 
also measured by LC/MS- MS using a custom- developed 
in- house assay. This was based on a published glucagon 
and GLP-1 method.25 The calibration matrix was also 
altered from buffer to depleted plasma to more closely 
match the study samples. The resulting assay gave a 
glucagon LLOQ of 4.3 pmol/L (15 pg/mL), with relative 
error less than ±25% and CV less than 25% over six repli-
cates. For the prospective study, active GLP-1 and GIP 
were measured by a customized Milliplex magnetic bead- 
based multianalyte human metabolic panel (Millipore 
HMHEMAG- 34K). The intra- assay and interassay CV was 
<10%, and the LLOQ was 0.8 pmol/L for active GLP-1 and 
0.3 pmol/L for GIP. Plasma oxyntomodulin was measured 
using a specific and sensitive mass- spectrometry validated 
immunoassay26: the intra- assay and interassay CV for this 
assay was <10% and the LLOQ was 5 pmol/L. Plasma 
glicentin was measured using the ELISA from Mercodia 
with intra- assay and interassay CV of <10%; the LLOQ 
was 3.1 pmol/L. This assay displays no cross- reactivity to 
glucagon, oxyntomodulin, GLP-1 and GLP-2. As noted 
in the results, the Alternative protocol for glucagon was 
selected for this study.
statistical analysis
All analyses were carried out using GraphPad Prism 
V.8.2.1 (GraphPad Software). For the comparison of 
assay performance, linear regression and Bland- Altman 
plots were used to compare the two Mercodia proto-
cols versus the reference LC/MS- MS assay. For analysis 
of the dynamic glucagon levels measured using the two 
Mercodia protocols and LC/MS- MS during the 75 g 
OGTT in patients after RYGB, a mixed- model repeated 
measures analysis was performed, using Tukey’s test to 
compare the glucagon levels at selected times after the 
dynamic stimulus was given. For the analysis of the gut 
hormone data from the MMT in the prospectively studied 
RYGB cohort, a mixed- model repeated measures anal-
ysis was performed, using Dunnett’s multiple compari-
sons test to compare the presurgery (Pre) data with the 
postsurgery data at 1, 3 and 12 months. The interactive, 
24- variable homeostatic model of assessment in default 
mode (HOMA2) was used to calculate %B (beta cell 
function) and %S (insulin sensitivity) using the fasting 
glucose and insulin values.27
ResulTs
Comparative performance of the Mercodia standard and 
alternative protocols versus lC/Ms-Ms
To understand the comparative performance of the 
assays for glucagon we analyzed 110 samples, derived 
from dynamic testing in patients after RYGB, in parallel 
using the Mercodia ELISA Standard and Alterna-
tive protocols, and the reference LC/MS- MS assay. 
Figure 1 shows the comparative performance of the 
ELISA protocols against LC/MS- MS. Linear regression 
(figure 1A,B) showed that both Standard and Alterna-
tive protocols exhibited overall negative proportional 
systematic biases (−19.3% and −57%, respectively). The 
Standard protocol exhibited a large positive constant 
bias (+10.1 pmol/L) whereas the constant bias was much 
smaller at +1.1 pmol/L for the Alternative protocol. The 
r2 statistic, as a measure of ‘goodness of fit’, was 0.1550 vs 
0.8121, respectively; this difference was reflected in the 
residual plots which demonstrated far smaller magnitude 
residuals with Alternative versus Standard (figure 1C,D). 
Bland- Altman plots (figure 1E,F) showed Standard 
had a mean bias of +8.1 pmol/L versus a mean bias of 
−4.6 pmol/L with Alternative. The 95% CI of agreement 
was much smaller with Alternative (−15.9 to +6.6 pmol/L) 
versus Standard (−27.2 to +43.5 pmol/L), consistent with 
the r2 statistic. The Alternative protocol did show a nega-
tive proportional systematic bias on the Bland- Altman 
plot (figure 1F). This suggests that this protocol’s inclu-
sion of the additional wash and incubation step leads to 
high analytical specificity in comparison to Standard, but 
there is a reduced recovery of glucagon in comparison 
with LC/MS- MS at higher values.
To investigate the reason for the positive bias in the 
Standard protocol, we examined the comparative data 
looking at a subset of non- diabetic participants who had 
undergone an OGTT after RYGB. The results in figure 2 
show that all three assays report similar fasting levels at 
baseline. Using the OGTT stimulus, there is an expecta-
tion that glucagon will be suppressed and indeed this is 
what is seen with the Alternative protocol and the LC/
MS- MS assay. However, the Standard protocol exhibits 
an artifactual post- OGTT rise persisting to 150 min after 
the glucose stimulus (mean difference (95% CI) vs LC/
MS- MS at 30 min: 24.5 pmol/L (5.9 to 43.1), adjusted 
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Figure 1 Comparative performance of Mercodia ELISA for glucagon using Standard and Alternative protocols versus LC/MS- 
MS as reference. Linear regression of Standard (A) and Alternative (B) versus LC/MS- MS: solid line shows linear regression line, 
dotted line of identity. Residuals plot for Standard (C) and Alternative (D) for linear regression. Bland- Altman plot for Standard 
(E) and Alternative (F): dotted line shows mean bias, gray shading 95% CI for agreement. LC/MS- MS, liquid chromatography 
combined with mass spectrometry.
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Figure 2 Variation in glucagon levels in Roux- en- Y gastric 
bypass (RYGB) patients during an oral glucose tolerance test 
(OGTT) as assessed by Mercodia Standard protocol (black), 
Alternative protocol (red) and LC/MS- MS (blue). Mean and 
95% CI plotted. Mixed- effects model analysis with Tukey’s 
test for multiple comparisons used to study the contrast 
between the assays at each time point. *Comparison of 
Standard versus Alternative. †Comparison of Standard 
versus LC/MS- MS. One symbol: p<0.05, two symbols: 
p<0.01. LC/MS- MS, liquid chromatography combined with 
mass spectrometry.
p=0.013). These post- OGTT samples are largely respon-
sible for the poor fit of the Mercodia Standard protocol 
values to the LC/MS- MS in figure 1A, C.
Proglucagon peptide dynamics in response to an MMT before 
and after RYGB surgery
Given its superior analytical specificity in comparison to 
the Standard protocol and its better analytical sensitivity 
compared with LC/MS- MS, we selected the Alternative 
protocol for analysis of glucagon levels from our prospec-
tively studied cohort of patients undergoing RYGB. In 
line with expectations, fasting glucose levels decreased 
significantly over time after RYGB surgery (mean differ-
ence (95% CI) between Pre vs 1 month: −2.4 mmol/L 
(−3.8 to –1.0), adjusted p=0.0005; Pre vs 3 months: −2.6 
(−3.9 to –1.3), adjusted p=0.0001; Pre vs 12 months: −3.3 
(−4.6 to –1.9), p<0.0001). During the MMT, we observed 
a shift of the peak towards the left with median time to 
peak (Tmax) for glucose decreasing to 22.5–30 min post-
operatively as opposed to 60 min when studied before 
surgery (table 2). The peak value (Cmax) for glucose 
was significantly reduced at 3 months after surgery 
(mean difference −1.5; 95% CI −2.9 to –0.04). There was 
a significant decrease in glucose area under the curve 
from 0 to 180 min (AUC0–180min) at 1, 3 and 12 months 
after surgery (figure 3A, table 2). Fasting insulin levels 
decreased significantly after surgery (mean difference 
(95% CI) between Pre vs 1 month: −8.4 mU/L (−14.0 to 
–2.8), adjusted p=0.0023; Pre vs 3 months: −9.2 (−15.0 to 
–3.3), adjusted p=0.0014; Pre vs 12 months: −12.9 (−17.7 
to –8.1), adjusted p<0.0001).
The HOMA2 analysis, using the fasting glucose and 
insulin values, showed no significant change in the beta cell 
function, but a significant and progressive postoperative 
increase in insulin sensitivity was observed (mean differ-
ence (95% CI) between Pre vs 1 month: 45.3% (12.9% to 
77.7%), adjusted p=0.0076; Pre vs 3 months: 60% (30.7% 
to 89.3%), adjusted p=0.0002; Pre vs 12 months: 107% 
(70.0% to 147.1%), adjusted p<0.0001). The change in 
shape of the postprandial insulin curve mirrored the 
one of glucose with a shift to an earlier median Tmax at 
30–45 min after RYGB surgery (figure 3B). There was a 
significant increase in the postprandial Cmax for insulin 
comparing Pre with 3 and 12 months (mean difference 
(95% CI) between Pre vs 1 month: 69.5 (−21.1 to 160.2), 
adjusted p=0.1455; Pre vs 3 months: 55.1 (8.9 to 101.4), 
adjusted p=0.0181; Pre vs 12 months: 47.7 (14.8 to 80.6), 
adjusted p=0.0044). There was a significant decrease in 
insulin AUC0–180min at 12 months after surgery but not at 1 
or 3 months (table 2).
The proglucagon- derived peptides showed divergent 
behavior after RYGB. Fasting glucagon levels were not 
changed at 1 month but decreased significantly after 
RYGB surgery at 3 and 12 months (mean difference 
(95% CI) between Pre vs 1 month: −0.5 pmol/L (−3.5 to 
2.6), adjusted p=0.9642; Pre vs 3 months: −4.48 (−6.3 to 
–2.7), adjusted p<0.0001; Pre vs 12 months: −4.5 (−6.8 
to –2.3), adjusted p=0.0004). Postprandially all patients 
responded to the MMT with an increase in glucagon 
secretion but we again observed a left shift of the Tmax 
to a median time of 15 min. There was a significantly 
reduced Cmax at 3 months compared with presurgery 
(mean difference (95% CI) between Pre vs 1 month: 
1.5 pmol/L (−9.0 to 12.4), adjusted p=0.9642; Pre vs 3 
months: −4.7 (−8.4 to –1.0), adjusted p=0.0118; Pre vs 12 
months: −4.3 (−9.8 to 1.2), adjusted p=0.1409). There was 
a significant decrease in glucagon AUC0–180min at 3 and 12 
months after surgery. Adjusting for the change in fasting 
baseline, we calculated the incremental AUC0–180min and 
there was no significant change in this value after surgery 
(figure 3C, table 2).
In contrast to glucagon, fasting GLP-1 levels did not 
show any significant change after surgery whereas post-
prandial GLP-1 Cmax increased significantly after 
surgery at 1, 3 and 12 months (mean difference (95% CI) 
between Pre vs 1 month: 27.7 pmol/L (14.0 to 41.5), 
adjusted p=0.0006; Pre vs 3 months: 44.9 (27.8 to 61.9), 
adjusted p<0.0001; Pre vs 12 months: 61.2 (43.5 to 78.9), 
adjusted p<0.0001). There was a marked, progressive and 
significant increase in GLP-1 AUC0–180min with time after 
surgery (figure 3D, table 2). Similar to GLP-1, fasting 
oxyntomodulin levels were not significantly altered after 
surgery but postprandial Cmax increased significantly at 
3 and 12 months after RYGB (mean difference (95% CI) 
between Pre vs 1 month: 21.9 pmol/L (−2.3 to 46.1), 
adjusted p=0.0783; Pre vs 3 months: 38.7 (19.4 to 57.9), 
adjusted p=0.0002; Pre vs 12 months: 32.2 (13.5 to 50.8), 
adjusted p=0.0010) with a left shift of Tmax to a median 
time of 30 min. Commensurately, there was a significant 
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Figure 3 Glucose (A), insulin (B), glucagon (C), active glucagon- like peptide-1 (GLP-1) (D), oxyntomodulin (E), glicentin (F) and 
GIP (G) levels during mixed- meal test (MMT). Mean and 95% CI plotted. Inset graphs show area under the curve (AUC) values 
over 0–180 min. Black, before surgery (Pre); red, 1 month after surgery; green, 3 months; blue, 12 months. Mixed- effects model 
analysis, Dunnett’s multiple comparisons test for repeated measures used to compare AUC values for Pre versus indicated 
times after surgery. *P<0.05; **p<0.01; ****p<0.0001. GIP, glucose- dependent insulinotropic peptide; OXM, oxyntomodulin; 
RYGB, Roux- en- Y gastric bypass.
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increase in oxyntomodulin AUC0–180min from 1 month 
onwards (figure 3E, table 2). Fasting glicentin levels 
remained unchanged after RYGB at 3 and 12 months 
compared with presurgery. However, after surgery, there 
was a large increase in Cmax (mean difference (95% CI) 
between Pre vs 3 months: 287.9 pmol/L (225.2 to 350.6), 
adjusted p<0.0001; Pre vs 12 months: 341.4 (287.6 to 
395.2), adjusted p<0.0001) with an accompanying signifi-
cant increase in glicentin AUC0–180min (figure 3F, table 2). 
Of all the proglucagon peptides, glicentin displayed the 
largest postprandial increase in secretion after RYGB, 
dwarfing GLP-1 and oxyntomodulin.
There was neither a statistically significant change in 
fasting, in postprandial GIP levels nor in GIP AUC0–180min 
(figure 3G, table 2), apart from a reduction in fasting 
levels at 3 months versus Pre (mean difference (95% CI) 
−10.3 pmol/L (−19.3 to –1.2), adjusted p=0.0266).
dIsCussIon
The key strengths of this prospective study are that we 
studied a well- characterized cohort of pre- diabetic/
diabetic participants undergoing RYGB in a single center 
with a standardized technique, and that the immuno-
assay employed for glucagon was validated against a refer-
ence LC/MS- MS assay. We found that for the Mercodia 
glucagon assay using extra incubation and wash steps 
(Alternative protocol) as an addition to the Standard 
protocol improved analytical specificity. Roberts et al 
have reported similar issues with the Standard protocol 
although in the context of lean patients who have under-
gone a total gastrectomy and Roux- en- Y reconstruction 
for cancer.24 Our data extends and validates this obser-
vation in the context of RYGB surgery for obese patients. 
The Mercodia assay, with Alternative protocol, is suit-
able for the measurement of glucagon levels in subjects 
who have undergone RYGB, although with some loss of 
recovery at higher levels.
Our specific assays allow us to distinguish the divergent 
behavior of the proglucagon- derived peptides in response 
to RYGB. Fasting glucagon reduced significantly in our 
study group after RYGB in alignment with the improve-
ment seen in glucose homeostasis and insulin sensitivity 
at 3 and 12 months. The MMT elicited an increase in 
glucagon secretion both preoperatively and postopera-
tively in response to the protein content of the stimulus,28 
unlike the OGTT stimulus. There was an overall reduc-
tion of glucagon AUC at 3 and 12 months and a reduction 
in the glucagon Cmax at 3 months, but the incremental 
AUC was similar between baseline and the postsurgical 
time points, suggesting that the magnitude of postpran-
dial stimulation of glucagon secretion after the MMT was 
similar and the reduced overall glucagon AUC is mainly 
driven by the lower starting level of glucagon. This reduc-
tion in fasting glucagon with unchanged postprandial 
secretion contrasts with the phenomenon of unchanged 
fasting levels and enhanced postprandial secretion seen 
with GLP-1 and oxyntomodulin.5 15
It is unknown what the mechanisms driving this change 
in glucagon dynamics are. Although GLP-1 is known to 
suppress glucagon secretion, fasting GLP-1 levels are 
not altered after surgery and cannot logically be driving 
a suppression in fasting glucagon levels. Similarly PYY 
has been shown to suppress glucagon secretion based 
on experiments in isolated islets,29 but fasting PYY levels 
are not altered after surgery.30 Notwithstanding the fact 
that endocrine somatostatin secretion is not altered after 
early time points following RYGB,31 we speculate that 
one possible mechanism for the fall in fasting insulin and 
glucagon secretion after RYGB may be an increase in para-
crine somatostatin secretion from islet delta cells.32 As for 
the postprandial glucagon response, this is unchanged 
after surgery and compatible with direct amino acid stim-
ulation of glucagon secretion by the MMT, with a left shift 
in Tmax due to accelerated delivery and digestion of the 
protein content after RYGB.33
Jorgensen et al, who employed an in- house assay directed 
to the C- terminus of glucagon, observed a reduced fasting 
glucagon level at 3 and 12 months after RYGB in concor-
dance with our findings. They observed an enhancement 
of postprandial glucagon secretion (as judged by incre-
mental glucagon AUC) from 1 week onwards persisting 
through 3 and 12 months which contrasts with our 
findings.5 15 Purnell et al showed a reduction in mean 
fasting glucagon level in diabetics undergoing RYGB 
and a progressive postsurgical enhancement of the peak 
glucagon response to an MMT stimulus at follow- up to 
24 months, at odds with our findings.12 However, they 
reported values of glucagon approximately 20- fold 
observed by us and other research groups, possibly due 
to a technical issue with their Millipore immunoassay, 
making their results difficult to interpret. Jorsal et al 
also used the Mercodia assay and the C- terminal assay to 
measure the response of glucagon to an MMT stimulus in 
eight patients undergoing RYGB at 3 months and 1 week 
prior to surgery, and at 1 week and 3 months after surgery. 
This study suggested no change in fasting glucagon levels 
at baseline, a small increase in peak glucagon secretion 
at 1 week, and, overall, no change in AUC for glucagon 
secretion after MMT, but the authors acknowledged that 
the small cohort number limited their statistical power.17 
Our study, on the other hand, used a larger cohort with 
greater statistical power to detect differences.
In contrast to glucagon, fasting oxyntomodulin showed 
little change after RYGB, but demonstrated marked and 
progressive increases in postprandial secretion as early 
as 1 month after RYGB, a pattern observed in other 
studies.2 7 9 26 As oxyntomodulin combines GLP-1 and 
glucagon activity34 this may contribute to the marked 
insulinotropy observed after RYGB in concert with GLP-1 
and therefore improved glucose disposal. We found that 
there was no difference in fasting glicentin after surgery, 
but massive postprandial increases were measured at 3 
and 12 months. It is known that this effect is present from 
1 week onwards after surgery.17 Glicentin inhibits gastric 
acid secretion35 as well as duodenal and jejeunal motility 
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in rats36 and appears to have a mild insulinotropic effect 
(less than that of glucagon) when infused in high doses 
into the pancreaticoduodenal artery in dogs.37 The effect 
of glicentin on metabolism in humans is more uncertain, 
with no metabolic effects seen in infusion studies,38 but 
it is likely, from the methodological point of view, that 
the increase in postprandial glicentin is the main cross- 
reactive species responsible for the poor performance of 
the Standard protocol compared with LC/MS- MS in the 
poststimulus samples.24
In a similar fashion to glucagon, previous studies on 
the behavior of GIP dynamics have shown discrepant 
results. Fasting GIP has been shown to fall in patients 
with diabetes who undergo RYGB39 but others have 
shown no change.40 In the study of Korner et al, there 
was no significant difference between RYGB patients and 
matched obese controls in terms of fasting GIP levels, but 
there was a marked reduction in postprandial secretion 
in response to a test meal.41 On the other hand, Laferrère 
and colleagues showed an increase in GIP secretion in 
response to an OGTT after RYGB compared with preop-
eratively.13 Our findings, in a larger cohort than used in 
these studies, suggest that, overall, there is no decided 
difference in GIP secretion either fasting or in response 
to an MMT, and that GIP may not contribute significantly 
to the increased postprandial insulinotropy and improve-
ment in glycemic control after RYGB.42
In summary, our study shows that, after RYGB, the fasting 
glucagon decreases but the postprandial glucagon secre-
tion to an MMT stimulus does not significantly change. 
This change in glucagon dynamics may contribute to the 
improvement in glycemia after surgery. Future studies 
on the feasibility of therapeutic strategies replicating the 
post- RYGB gut hormone milieu (the so- called ‘medical 
bypass’) may benefit from inclusion of a glucagon antag-
onist43 to investigate the contribution of glucagonostasis 
to the benefits of RYGB.
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